NCT04789096: An ongoing trial by Breast Cancer Trials, Australia and New Zealand
This trial is ongoing. It must report results 5 months, 2 weeks from now.
Full data
| Full entry on ClinicalTrials.gov | NCT04789096 |
|---|---|
| Title | A Phase II, Two-arm, Non-comparative, Multicentre Study of Tucatinib (ONT-380), Pembrolizumab and Trastuzumab in Patients With Pre-treated Advanced HER2-positive Breast Cancer |
| Results Status | Ongoing |
| ACT or pACT? | This is what FDAAA officially calls an "Applicable Clinical Trial" |
| Start date | March 7, 2023 |
| Completion date | June 4, 2025 |
| Required reporting date | June 4, 2026, midnight |
| Actual reporting date | None |
| Date last checked at ClinicalTrials.gov | Dec. 12, 2025 |
| Days late | None |